Ariana Pharma | GenomeWeb

Ariana Pharma

The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.

NEW YORK (GenomeWeb News) – The WIN Consortium, an International personalized medicine initiative, will use €3 million ($3.9 million) in funding from the European Union to launch an effort to provide tailored cancer treatment regimens to patients based on genetic analysis, the consortium said tod

NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.

NEW YORK (GenomeWeb News) – Ariana Pharma announced today an exclusive distribution deal with CTC Laboratory Systems covering Japan.

Ariana Pharma, a provider of an association rules-based clinical data analysis technology, has tapped Mariana Kuras to serve as its chief technology officer.

The goal of the project, called Hepachronix, is to gain a better understanding of how liver fibrosis progresses from early, mild stage to debilitating diseases such as cirrhosis and hepatoma carcinoma.

Ariana Pharma announced this week that the FDA will use its KEM Biomarker technology to "systematically identify potential genomic 'fingerprints' and develop recommendations for the analysis of genomic data prior to submission of biomarker signatures."

The FDA will use Ariana Pharma's biomarker data mining technology to review and analyze data submitted through a voluntary data submission program.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.